Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
在美国,一项首次人体试验(HVTN 136/HPTN 092)研究了抗HIV-1单克隆抗体PGT121.414.LS单独使用以及与VRC07-523LS联合使用时,在美国未感染HIV的成年人中的安全性、耐受性、药代动力学和中和活性。该研究为一项开放标签、随机对照的I期临床试验。
期刊:Lancet HIV
影响因子:
doi:10.1016/S2352-3018(24)00247-9
Edupuganti, Srilatha; Hurt, Christopher B; Stephenson, Kathryn E; Huang, Yunda; Paez, Carmen A; Yu, Chenchen; Yen, Catherine; Hanscom, Brett; He, Zonglin; Miner, Maurine D; Gamble, Theresa; Heptinstall, Jack; Seaton, Kelly E; Domin, Elizabeth; Lin, Bob C; McKee, Krisha; Doria-Rose, Nicole; Regenold, Stephanie; Spiegel, Hans; Anderson, Maija; McClosky, Nadia; Zhang, Lily; Piwowar-Manning, Estelle; Ackerman, Margaret E; Pensiero, Michael; Dye, Bonnie J; Landovitz, Raphael J; Mayer, Kenneth; Siegel, Marc; Sobieszczyk, Magdalena; Walsh, Stephen R; Gama, Lucio; Barouch, Dan H; Montefiori, David C; Tomaras, Georgia D